A carregar...
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6469186/ https://ncbi.nlm.nih.gov/pubmed/30871014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12010037 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|